
SECTION I – AWARD DATA – 5U62PS004009-03 REVISED**Award Calculation (U.S. Dollars)**

| | |
|-----------------------------|-----------|
| Salaries and Wages | \$203,619 |
| Fringe Benefits | \$99,773 |
| Personnel Costs (Subtotal) | \$303,392 |
| Supplies | \$3,798 |
| Travel Costs | \$2,196 |
| Other Costs | \$10,539 |
| Consortium/Contractual Cost | \$256,763 |

| | |
|-----------------------------------|------------------|
| Federal Direct Costs | \$576,688 |
| Federal F&A Costs | \$63,106 |
| Approved Budget | \$639,794 |
| Federal Share | \$639,794 |
| TOTAL FEDERAL AWARD AMOUNT | \$639,794 |

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$479,845

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

04 \$676,236
05 \$676,236

Fiscal Information:

CFDA Number: 93.944
EIN: [REDACTED]
Document Number: 004009PS15

| | | | | |
|----|---------|-----------|-----------|-----------|
| IC | CAN | 2015 | 2016 | 2017 |
| PS | 9391154 | \$639,794 | \$676,236 | \$676,236 |

| SUMMARY TOTALS FOR ALL YEARS | | |
|------------------------------|------------|-------------------|
| YR | THIS AWARD | CUMULATIVE TOTALS |
| 3 | \$639,794 | \$639,794 |
| 4 | \$676,236 | \$676,236 |
| 5 | \$676,236 | \$676,236 |

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

CDC Administrative Data:

PCC: N / OC: 4151 / Processed: ERAAPPS 03/05/2015

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U62PS004009-03 REVISED

For payment information see Payment Information section in Additional Terms and Conditions.

INSPECTOR GENERAL: The HHS Office Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhtips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous. This note replaces the Inspector General contact information cited in previous notice of award.

SECTION III – TERMS AND CONDITIONS – 5U62PS004009-03 REVISED

This award is based on the application submitted to, and as approved by, CDC on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The HS Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

This award has been assigned the Federal Award Identification Number (FAIN) U62PS004009. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Treatment of Program Income:

Additional Costs

SECTION IV – PS Special Terms and Conditions – 5U62PS004009-03 REVISED

Funding Opportunity Announcement (FOA) Number: PS13-1302

Award Number: 5 U62 PS004009-03 AMENDMENT (2)

ADDITIONAL TERMS AND CONDITIONS OF THIS AWARD

The purpose of this revised Notice of Award is to award the final funding in the amount of **\$479,845**. Previously, **\$159,949** had been awarded, making the current total available award amount **\$639,794** for the Year 3 budget period which is **January 1, 2015** through **December 31, 2015** through. The distribution of new funds is as follows:

Component A, Case Surveillance **\$479,845**

REPORTING REQUIREMENTS UPDATE:

Annual Federal Financial Report (FFR, SF-425): The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted through eRA Commons no later than 90 days after the end of the calendar quarter in which the budget period ends. The FFR for this budget period is due to the GMS/GMO by March 31, 2016. Reporting timeframe is January 1, 2015 through December 31, 2015.

The FFR should only include those funds authorized and disbursed during the timeframe covered by the report. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) cash transaction data. All Federal reporting in PMS is unchanged.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the grantee is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

FFR (SF-425) instructions for CDC Grantees are available at <http://grants.nih.gov/grants/forms.htm>. For further information, contact GrantsInfo@nih.gov. Additional resources concerning the eFSR/FFR system, including a User Guide and an on-line demonstration, can be found on the eRA Commons Support Page: <http://www.cdc.gov/od/pgo/funding/grants/eramain.shtm>.

GENERAL REQUIREMENTS

Prior Approval: All requests requiring prior approval must be submitted on a cover letter including two signatures: 1) the authorized official of the grantee organization, 2) the principal investigator or program or project director named on this NoA. The grantee must submit these requests by August 31, 2015 (no later than 120 prior to this budget period's end date of December 31, 2015). Any requests that reflect only one of the required signatures will be returned unprocessed. Additionally, any request involving funding issues must include an itemized budget and a narrative justification.

The following types of requests require prior approval:

1. Use of unobligated funds from a prior budget period (carryover). The CDC Program Office and PGO strongly encourages that all requests for use of unobligated funds be submitted on or before May 1, 2015 so that sufficient time is allowed for processing your request and providing you (the grantee) sufficient time to expend the funds by December 31, 2015.
2. Lift funding restriction, withholding, or disallowance
3. Redirection of funds
4. Change in scope
5. Implement a new activity or enter into a sub-award that is not specified in the most recently approved budget:
 - Apply for supplemental funds
 - Response to the objective/technical review statement
 - Change in key personnel
 - Extensions
 - Conferences or meetings that exceed the cost threshold

Key Personnel Changes: In accordance with 2 CFR Parts 200.308 and 215.25©(2) & (3), CDC grantees must obtain prior approval from CDC for (1) change in the project director/principal investigator, business official, authorized organizational representative or other key persons specified in the FOA, application, or award document; and (2) the disengagement from the project for more than three months, or a 25% reduction in time devoted to the project, by the approved project director or principal investigator. CDC requests the courtesy of notifying the CDC program representatives when notice of changes or disengagement has been provided to the project.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

Programmatic Contact:

Darrin Brown, Project Officer
Centers for Disease Control
Division of HIV/AIDS Prevention
1600 Clifton Rd, MS E-58
Atlanta, GA 30333
Telephone: 404-639-5181
Email: DBrown2@CDC.GOV

STAFF CONTACTS

Grants Management Specialist: Louvern Asante
Centers for Disease Control and Prevention (CDC)
Procurement and Grants Office
Koger Center, Colgate

